Based on the finding that PI3K/PTEN/HSP90-regulated ILK upregulation induces non-canonical IQGAP1/Ras/ERK1/2-mediated NF-κB activation and growth advantages in gastric cancer cells, targeting this pathway may be beneficial when used in combination with other anticancer agents. The gene discussed is MAPK3; the disease is gastric cancer.